PEG MGF For Lab Research

PEG-MGF Peptide | Buy PEG-MGF UK | Research Use Only

PEG-MGF — Pegylated Mechano Growth Factor — is a synthetic, PEGylated analogue of the 24-amino acid C-terminal E-domain peptide of IGF-1Ec (Mechano Growth Factor, the human skeletal muscle-specific splice variant of IGF-1 generated by alternative splicing of exon 5 to exon 6 following mechanical overload or muscle injury), conjugated to polyethylene glycol (PEG) via a succinyl linker to extend its in vivo half-life from approximately 5–7 minutes for native MGF to 24–72 hours — making it the only research-viable form of the MGF E-peptide for in vivo pharmacokinetic, satellite cell activation, and tissue repair studies — and the defining pre-clinical research tool for investigating the distinct, IGF-1 receptor-independent proliferative signalling axis of the MGF E-domain, satellite cell biology, skeletal muscle regeneration, age-related sarcopenia, cardiac protection, neurogenesis, and the broader mechanosensitive arm of the IGF-1 splice variant system. Buy PEG-MGF in the UK from Peptides Lab UK with >99% HPLC-verified purity, batch-specific COA, and fast UK dispatch for laboratory and in vitro research use only.

Distributed by Peptides Lab UK in lyophilised format for controlled laboratory research. Each batch is independently verified for purity. This compound is handled strictly in pre-clinical settings with no applications in human or veterinary medicine.

What Is PEG-MGF?

PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic peptide derived from the unique C-terminal E-domain of IGF-1Ec — the mechanosensitive splice variant of the insulin-like growth factor 1 gene expressed locally in skeletal muscle and other tissues in response to mechanical stretch, injury, exercise, and hypoxia.

Understanding the IGF-1 Splice Variant System

The IGF-1 gene spans six exons and generates multiple distinct mRNA transcripts through alternative promoter usage and C-terminal alternative splicing. The most important isoforms in muscle research are:

• IGF-1Ea — the predominant circulating form, produced in the liver in response to GH, responsible for systemic anabolic and proliferative IGF-1 signalling via the IGF-1 receptor (IGF-1R)
• IGF-1Ec (MGF in humans; IGF-1Eb in rodents) — the mechanosensitive splice variant, expressed locally in skeletal muscle in response to stretch, overload, or damage, characterised by a 49 bp insert (52 bp in rodents) within exon 5 that creates a reading frame shift and generates a unique 24–25 amino acid C-terminal E-domain peptide distinct from the E-domain of IGF-1Ea

The 24-amino acid C-terminal E-domain peptide of IGF-1Ec — commonly designated MGF-24aa or MGF E-peptide — is the biologically active fragment studied in the majority of synthetic MGF research, including PEG-MGF. Critically, this E-domain peptide is structurally distinct from the N-terminal 70-amino acid mature IGF-1 sequence shared by all isoforms and is therefore not equivalent to, and does not replicate the pharmacology of, systemic IGF-1 or IGF-1 LR3.

Why PEGylation Is Essential for MGF Research

Native MGF E-peptide has a plasma half-life of approximately 5–7 minutes — too brief for most in vivo experimental paradigms to achieve meaningful tissue-level exposure. PEGylation — the covalent attachment of polyethylene glycol (PEG) chains via a succinyl linker — surrounds the peptide with a steric hydrophilic shield that dramatically increases hydrodynamic radius, reduces renal filtration, and provides protection from proteolytic degradation. The result is a half-life extension to 24–72 hours — making PEG-MGF the standard in vivo-capable form of the MGF E-peptide in all pre-clinical research requiring sustained systemic exposure, time-course pharmacokinetic studies, or repeated-dosing paradigms.

The MGF Receptor — An Important Research Context

The receptor for the MGF E-peptide has not been formally identified. Yang and Goldspink (2002) demonstrated that MGF E-peptide’s proliferative effect on C2C12 myoblasts was not blocked by an IGF-1 receptor-neutralising antibody — establishing that MGF signals via an IGF-1R-independent mechanism. Subsequent research proposed that MGF activates ERK signalling (but not Akt), in contrast to IGF-1R activation which drives both PI3K/Akt and MAPK/ERK pathways. This signalling divergence — IGF-1R-independent ERK activation vs IGF-1R-dependent Akt/mTOR activation — is one of the central research questions in the MGF field and is the mechanistic basis for the functionally distinct roles of MGF (proliferation, satellite cell activation, anti-differentiation) and mature IGF-1 (differentiation, protein synthesis, hypertrophy) in the sequential muscle regeneration programme.

Also Known As

• PEG IGF-1Ec / PEG IGF-1Eb (rodent)
• Pegylated Mechano Growth Factor
• PEG Myotrophin
• MGF-24aa-E peptide (PEGylated)
• Sequence: PEG-Suc-Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-Cys

How Does PEG-MGF Work?

IGF-1R-Independent Satellite Cell Activation — The Primary Research Mechanism

The most extensively characterised property of the MGF E-peptide is its ability to activate quiescent muscle satellite cells — the resident stem cells of adult skeletal muscle — and promote their proliferation while simultaneously inhibiting terminal differentiation. This dual action (proliferate but don’t yet differentiate) is mechanistically distinct from mature IGF-1, which primarily drives differentiation, and explains why MGF and IGF-1Ea have sequential, complementary roles in the muscle regeneration programme:

1. Acute phase (0–24 hours post-injury): MGF/IGF-1Ec mRNA peaks locally in damaged muscle — confirmed at T24 in human muscle following eccentric exercise — activating satellite cells to exit quiescence and enter the cell cycle
2. Proliferative phase (24–72 hours): Satellite cells proliferate, fuelled by MGF signalling, while differentiation is suppressed
3. Differentiation phase (72–120+ hours): IGF-1Ea mRNA rises as MGF declines — shifting the programme toward myoblast differentiation, myotube fusion, and myofibre maturation

PEG-MGF allows researchers to deliver the MGF signal at controlled intervals across this entire time course without the pharmacokinetic limitations of native MGF.

IGF-1R-Independent ERK Pathway Activation

MGF E-peptide activates ERK signalling in satellite cells and myoblasts via a receptor distinct from the IGF-1R. This ERK-without-Akt profile supports cellular proliferation and survival while maintaining cells in a proliferative rather than differentiated state — contrasting sharply with IGF-1’s PI3K/Akt/mTOR-dominant signalling, which drives protein synthesis and differentiation. The identification of a distinct, non-IGF-1R MGF receptor remains an active research goal.

Myoblast Proliferation and Anti-Differentiation

Yang and Goldspink (2002) in FEBS Letters — the foundational paper for synthetic MGF E-peptide research — confirmed that MGF E-domain peptide increases myoblast proliferation while inhibiting terminal differentiation of C2C12 cells, in contrast to mature IGF-1 which primarily promotes differentiation with a lesser proliferative effect. This functional divergence between MGF and mature IGF-1 is the pharmacological basis for using PEG-MGF in research designs where satellite cell pool expansion — rather than direct hypertrophy — is the experimental variable.

Age-Dependent MGF Expression Decline

MGF expression in response to exercise and muscle damage is substantially lower in aged muscle than in young muscle — a well-replicated finding from both rodent studies and human exercise research by Hameed, Goldspink, and colleagues. The MGF E-peptide has been shown to significantly increase the proliferative lifespan and delay senescence of satellite cells isolated from neonatal and young adult human muscle, while having attenuated effects in cells from older adults — establishing an age-dependent satellite cell responsiveness to MGF that underpins its utility as a sarcopenia and muscle ageing research tool.

ALS and Dystrophic Muscle Models

MGF E-peptide was shown to increase progenitor cell populations in ALS (amyotrophic lateral sclerosis), dystrophic, and normal rodent muscle — establishing a research application in neuromuscular disease models beyond straightforward exercise-induced muscle damage. The IGF-1Ec isoform is expressed in ALS patients’ muscle, and its modulation by synthetic MGF E-peptide represents a potential research strategy for understanding progenitor cell dynamics in progressive muscle wasting conditions.

Cardiac Protection — MGF and the Heart

The MGF E-domain peptide has been shown to increase proliferation and migration of mesenchymal bone marrow-derived stem cells and to stimulate pro-angiogenic activity in human vascular endothelial cells — mechanisms directly relevant to myocardial repair following ischaemic injury. Paul H. Goldspink’s laboratory at the Medical College of Wisconsin has specifically characterised IGF-1 isoform activity in cardiac tissue, demonstrating MGF’s role in preventing cardiomyocyte death, preserving contractility, and preventing pathological hypertrophy following myocardial infarction in animal studies. PEG-MGF’s extended half-life makes it the appropriate tool for in vivo cardiac post-ischaemia research models.

Neuroprotection and Neurogenesis

MGF expression has been confirmed in neurogenic areas of the mouse brain, with levels declining with age. The 2017 Tang et al. Molecular Brain study confirmed that MGF overexpression significantly increased the number of proliferative cells (BrdU+) in the dentate gyrus of the hippocampus and subventricular zone — the primary adult neurogenic niches — establishing that MGF promotes adult hippocampal neurogenesis. A potent neuroprotective effect of the autonomous C-terminal IGF-1Ec peptide has also been confirmed in brain ischaemia models. PEG-MGF is used in neuroprotection and neurogenesis research as the long-acting MGF E-peptide tool for CNS studies.

Cartilage and Bone Research

Pre-clinical rabbit cartilage healing studies demonstrated that MGF-based peptides produce meaningful improvements in articular cartilage repair — a tissue with notoriously limited intrinsic regenerative capacity. MGF-24aa-E peptide also regulates migration and differentiation of bone marrow mesenchymal stem cells, and promotes osteoblast proliferation in bone-defect healing models — expanding PEG-MGF’s research utility to both cartilage biology and bone regeneration research.

What Does PEG-MGF Do in Research?

In laboratory and pre-clinical settings, PEG-MGF is studied as the defining long-acting MGF E-peptide research tool across skeletal muscle, cardiac, neurological, and orthopaedic biology:

• Satellite cell biology — activation from quiescence, proliferative lifespan extension, fusion potential, and anti-differentiation signalling
• Skeletal muscle regeneration — myoblast proliferation, myofibre formation, and sequential IGF-1 splice variant programme research
• IGF-1R-independent signalling — ERK pathway activation, receptor identification studies, and signalling divergence from mature IGF-1
• Exercise-induced muscle damage — IGF-1Ec mRNA expression time-course, MGF peak at T24 hours, and satellite cell activation kinetics
• Sarcopenia and muscle ageing — age-dependent MGF expression decline, elderly satellite cell responsiveness, and proliferative lifespan studies
• Muscle wasting disease models — ALS, muscular dystrophy, progenitor cell pool expansion, and MGF E-peptide rescue
• Cancer cachexia and muscle atrophy — anabolic signalling in wasting models and body weight restoration research
• Cardiac protection and regeneration — cardiomyocyte survival, post-MI contractility, and pathological hypertrophy prevention
• Angiogenesis and vascular repair — endothelial cell pro-angiogenic activity, VEGF axis crosstalk, and collateralisation
• Bone marrow mesenchymal stem cell biology — migration, differentiation, and cardiac stem cell transplantation models
• Cartilage repair — articular cartilage regeneration and osteoarthritis prevention models
• Osteoblast biology and bone healing — osteoblast proliferation, bone-defect healing, and bone remodelling research
• Neuroprotection and brain ischaemia — C-terminal IGF-1Ec E-peptide neuroprotective activity in MCAO models
• Hippocampal neurogenesis — BrdU+ proliferative cell expansion, dentate gyrus biology, and adult neurogenesis
• PEGylation pharmacokinetics — half-life extension, steric shielding, proteolysis resistance, and systemic vs local delivery comparison
• Comparative IGF-1 isoform research — MGF (IGF-1Ec) vs IGF-1Ea vs IGF-1 LR3 proliferation/differentiation pharmacology
• WADA-prohibited compound detection — MGF and PEG-MGF detection methodology and anti-doping assay development
• Gene doping research — IGF-1Ec gene expression constructs and MGF overexpression transgenic model characterisation

What Do Studies Say About PEG-MGF?

The Foundational Paper — Yang and Goldspink 2002

The landmark 2002 study by Yang and Goldspink published in FEBS Letters established the mechanistic foundation for all synthetic MGF research. Using C2C12 mouse myoblasts, the study confirmed that the MGF E-domain peptide increases myoblast proliferation while inhibiting terminal differentiation — and critically, that this effect was maintained in the presence of a neutralising anti-IGF-1R antibody — directly establishing that MGF E-peptide signals via an IGF-1R-independent mechanism. This receptor-independence distinguishes MGF from mature IGF-1 at a fundamental pharmacological level and remains the primary mechanistic framework for PEG-MGF research design.

Human Exercise Study — MGF mRNA Peaks at 24 Hours Post-Eccentric Exercise

The human in vivo study by Philippou et al. (2009) and earlier Mills et al. (2007, Growth Hormone & IGF Research) confirmed that following 300 eccentric lengthening contractions of the knee extensors in healthy young men, MGF mRNA expression peaked at 24 hours post-exercise while IGF-1Ea mRNA rose later at 72 hours — providing direct in vivo human evidence of the sequential IGF-1 splice variant programme and establishing the temporal window for MGF-mediated satellite cell activation in physiological muscle damage. This temporal data underpins the research design rationale for PEG-MGF’s extended half-life: it must be present during the acute 0–24-hour MGF signalling window and maintained through the proliferative phase.

Satellite Cell Proliferative Lifespan — Kandalla et al. 2011

The study by Kandalla, Goldspink, Butler-Browne, and Mouly published in Acta Physiologica (2011) evaluated MGF-24aa-E peptide on primary human satellite cells isolated from donors across age groups. The study confirmed that MGF E-peptide significantly increased the proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult subjects, with hypertrophy in all culture ages and a significant decrease in reserve (quiescent) cell percentage — directly establishing the age-dependent responsiveness of human satellite cells to MGF stimulation. This is the most direct human cell dataset supporting the research use of PEG-MGF in sarcopenia and ageing biology.

Neuroprotection in Brain Ischaemia — Dluzniewska et al. 2005

The 2005 study by Dluzniewska et al. published in FASEB Journal confirmed a strong neuroprotective effect of the autonomous C-terminal IGF-1Ec E-peptide in a rat brain ischaemia model — with potency comparable to or exceeding that of full-length IGF-1 at equivalent doses. This neuroprotection was dose-dependent and mechanistically distinct from IGF-1R-mediated neuroprotection — providing the foundational evidence for PEG-MGF’s use in CNS neuroprotection research.

The Contested Replication — Baehr et al. 2014

In the interests of research rigour, the contested replication study by Baehr et al. published in the American Journal of Physiology-Endocrinology and Metabolism (2014) is an important dataset. Using C2C12 cells and primary human skeletal muscle myoblasts, concentrations of MGF synthetic peptide up to 500 ng/mL failed to increase proliferation in either cell type — in contrast to the positive proliferative responses obtained with mature IGF-1 and full-length IGF-1Ec in the same experimental system. The study highlighted that no endogenous MGF E-peptide has been isolated from in vivo tissue — raising questions about whether the synthetic 24-aa peptide faithfully replicates any endogenous cleavage product. This mechanistic debate has been addressed in subsequent literature as reflecting differences in cell culture conditions, peptide batches, and choice of IGF-1 axis inhibitors — and does not invalidate the substantial positive evidence base — but represents an important research context requiring careful experimental design.

Neurogenesis — Tang et al. 2017

The 2017 study by Tang, Podratz, Lange et al. published in Molecular Brain confirmed endogenous MGF expression in neurogenic brain areas with age-dependent decline, and that transgenic MGF overexpression significantly increased BrdU+ proliferative cell counts in the dentate gyrus and subventricular zone of the hippocampus — establishing MGF as a neurogenesis-promoting factor in ageing brain biology and directly relevant to PEG-MGF neurogenesis and neuroprotection research applications.

Key Cited Studies

• Yang SY & Goldspink G (2002) — Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett 522(1–2):156–160. DOI: 10.1016/S0014-5793(02)02918-6. PMID: 12095637
• Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD (2003) — Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol 547(1):247–254. DOI: 10.1113/jphysiol.2002.032136. PMC2342623
• Kandalla PK, Goldspink G, Butler-Browne G, Mouly V (2011) — Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev 132(4):154–162. DOI: 10.1016/j.mad.2011.02.007. PMID: 21354439
• Dluzniewska J et al. (2005) — A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J 19(13):1896–1898. DOI: 10.1096/fj.05-3786fje. PMID: 16162746
• Tang JJ, Podratz JL, Lange M et al. (2017) — Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain. Mol Brain 10:23. DOI: 10.1186/s13041-017-0304-0. PMC5494097
• Matheny RW Jr, Nindl BC, Adamo ML (2010) — Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 151(3):865–875. DOI: 10.1210/en.2009-1217. PMC2840678
• Zabłocka B, Goldspink PH, Goldspink G, Górecki DC (2012) — Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol 3:131. DOI: 10.3389/fendo.2012.00131. PMC3485521
• Baehr LM, Tunzi M, Bodine SC (2014) — Mechano-growth factor peptide, the COOH terminus of unprocessed IGF-1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab 306(2):E150–E156. DOI: 10.1152/ajpendo.00408.2013. PMID: 24280126

PEG-MGF vs Related IGF-1 Axis and Muscle Repair Research Peptides

Feature	PEG-MGF	IGF-1 LR3	Native MGF (non-PEG)	BPC-157
Origin	IGF-1Ec C-terminal E-domain (PEGylated)	IGF-1 analogue with Arg3 substitution and 13-aa extension	IGF-1Ec C-terminal E-domain (native)	Human gastric juice BPC fragment
Receptor	IGF-1R-independent (unidentified) — ERK activation	IGF-1R (high affinity) — PI3K/Akt/mTOR	IGF-1R-independent — ERK activation	VEGFR2, GHR, HO-1, FAK-paxillin (multi-pathway)
Primary Effect	Satellite cell activation, proliferation, anti-differentiation	Protein synthesis, anabolic hypertrophy, differentiation	As PEG-MGF but minutes half-life	Tendon/tissue repair, angiogenesis, cytoprotection
Half-Life	24–72 hours (PEG-extended)	~20–30 hours	~5–7 minutes	<30 minutes
In Vivo Viability	Yes — PEG extends for pharmacokinetic studies	Yes	No — too short for most in vivo paradigms	Yes
IGF-1R Activity	No — IGF-1R-independent	Yes — IGF-1R agonist	No — IGF-1R-independent	No direct IGF-1R activity
Akt/mTOR	No (ERK, not Akt)	Yes (primary pathway)	No (ERK, not Akt)	Indirect (via GHR/JAK2 pathway)
Satellite Cell Research	Yes — primary application	Yes (via IGF-1R)	Yes (in vitro)	Limited
Cardiac Research	Yes — cardiomyocyte survival, anti-pathological hypertrophy	Yes — cardiac hypertrophy models	Limited (half-life too short)	Yes — fistula, arrhythmia models
Neuroprotection	Yes — brain ischaemia, neurogenesis	Yes	Limited	Yes
WADA Status	Prohibited	Prohibited	Prohibited	Prohibited
Best Research Use	Satellite cell biology, sarcopenia, cardiac/neural repair	Systemic anabolic IGF-1 signalling, protein synthesis	In vitro mechanistic studies only	Tissue repair, GI, broad cytoprotection

Quality & Purity Assurance

Every batch of PEG-MGF from Peptides Lab UK is:

• >99% pure — HPLC and mass spectrometry verified
• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Buy PEG-MGF UK — Product Specifications

Property	Detail
Full Name	PEG-MGF / Pegylated Mechano Growth Factor
Also Known As	PEG IGF-1Ec, PEG Myotrophin, Pegylated MGF E-peptide
Core Peptide Sequence	PEG-Suc-Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-Cys
Amino Acids (core peptide)	24 (C-terminal IGF-1Ec E-domain peptide)
Modification	Polyethylene glycol (PEG) via succinyl linker
Core Peptide MW	~2,867 Da (varies with PEG MW)
Molecular Formula (core)	C₁₂₁H₂₀₀N₄₂O₃₉
Half-Life (native MGF)	~5–7 minutes
Half-Life (PEG-MGF)	24–72 hours
Primary Mechanism	IGF-1R-independent ERK activation; satellite cell proliferation
Purity	>99% (HPLC verified)
Form	Lyophilised powder
Storage	Store dry at -20°C; protect from light; do not shake
Reconstitution	Bacteriostatic water — swirl gently, do not vortex; store at 2–8°C post-reconstitution

PEG-MGF Research Applications

PEG-MGF (Pegylated Mechano Growth Factor) UK is supplied strictly for the following in vitro and pre-clinical research uses:

• Satellite cell activation, proliferative lifespan extension, and anti-differentiation biology
• Skeletal muscle regeneration — myoblast proliferation and sequential IGF-1 splice variant programme research
• IGF-1R-independent ERK signalling — receptor identification and signalling divergence from mature IGF-1
• Exercise-induced muscle damage models — IGF-1Ec mRNA time-course and satellite cell kinetics
• Sarcopenia and muscle ageing — age-dependent MGF response decline and human satellite cell responsiveness
• Muscle wasting models — ALS, muscular dystrophy, and progenitor cell pool expansion research
• Cancer cachexia and muscle atrophy — anabolic signalling rescue research
• Cardiac protection — cardiomyocyte survival, post-MI contractility, pathological hypertrophy prevention
• Angiogenesis and vascular repair — endothelial pro-angiogenic activity and collateralisation
• Bone marrow mesenchymal stem cell migration, differentiation, and cardiac transplantation models
• Articular cartilage regeneration and osteoarthritis prevention research
• Osteoblast proliferation and bone-defect healing models
• Neuroprotection — brain ischaemia C-terminal IGF-1Ec E-peptide models
• Hippocampal neurogenesis — dentate gyrus BrdU+ proliferative cell expansion
• PEGylation pharmacokinetics — half-life, steric shielding, and systemic vs local delivery research
• Comparative IGF-1 isoform pharmacology — PEG-MGF vs IGF-1Ea vs IGF-1 LR3
• WADA-prohibited compound detection and anti-doping assay development

Why Buy PEG-MGF UK from Peptides Lab UK?

Peptides Lab UK is a trusted UK peptides supplier providing research-grade compounds verified by independent HPLC testing. When you buy PEG-MGF in the UK from us, you receive:

99% purity, HPLC and MS verified, third-party tested

• Full COA documentation per batch
• Fast same-day UK dispatch with tracked delivery
• Competitive pricing with bulk research discounts available
• Trusted by researchers across the UK and Europe

Research Disclaimer

All products supplied by Peptides Lab UK are intended strictly for in vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. PEG-MGF (Pegylated Mechano Growth Factor) is not a licensed medicine or drug and has not been approved by the MHRA, FDA, or any regulatory authority for use in humans or animals. PEG-MGF and MGF are classified as prohibited substances under WADA anti-doping regulations and are not approved for use in competitive sport. Researchers should note that the receptor mediating the IGF-1R-independent effects of the MGF E-peptide has not been formally identified, and that independent replication of some proliferative effects has been inconsistent across cell culture systems — both of which are accurately reflected in the published literature and should inform experimental design. All citations on this page refer to pre-clinical and peer-reviewed research and do not constitute a claim of safety or therapeutic efficacy. Peptides Lab UK accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.